Navigation Links
Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent

Moffitt Research Presented at 9th International Symposium on Myelodysplastic Syndromes

TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented today by Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, at the 9th International Symposium on MDS currently taking place in Florence, Italy. Breakthrough data presented at the meeting showed that Revlimid, or lenalidomide, can provide long-term survival benefit and prevent disease progression in MDS patients with chromosome 5q deletion.

"These landmark data demonstrate that Revlimid, in many cases, can help patients with MDS live transfusion free for several years. More importantly, we found that Revlimid can provide a significant long-term survival advantage, with 87 percent of cytogenic responders having a ten-year survival estimate," said Dr. List, Professor of Oncology and Medicine and Chief, Division of Malignant Hematology at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

The updated data presented by Dr. List at this year's Symposium showed that patients with MDS with chromosome 5q deletion who received Revlimid were able to remain transfusion free for an average of 2.2 years and, after four years, patients were still responding to treatment. Additionally, among patients who showed a cytogenic response to Revlimid, 87 percent had a ten year survival estimate compared to only four percent of non-cytogenic responders.

Additional data from a retrospective analysis of a German database on MDS patients treated with Revlimid was also presented at the Symposium and showed that Revlimid can also prevent dis ease progression in patients with MDS with chromosome 5q deletion. This is noteworthy because, according to the MDS Foundation, approximately 30 percent of patients diagnosed with MDS will typically progress to acute myeloid leukemia (AML). Patients receiving Revlimid also had a statistically significant overall survival advantage.

MDS, a cancer in which the bone marrow fails to make enough functioning blood cells, affects 300,000 people worldwide killing 60,000 to 70,000 a year. MDS patients suffer from anemia and fatigue and need whole-body blood transfusions as much as twice a month. Repeated transfusions can lead to a toxic buildup called "iron overload" that severely damages the heart, liver and pancreas, and patients eventually succumb to the disease.

Revlimid is indicated for the treatment of patients with transfusion- dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is also used as treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida on the University of South Florida campus, H. Lee Moffitt Cancer Center & Research Institute (www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of America's Best Hospitals for cancer. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

    For more information, contact:

    Nancy Johnson

    (813) 745-1478

    

nancy.johnson@moffitt.org

Lee Moffitt Cancer Center & Research Institute

CONTACT: Nancy Johnson of H. Lee Moffitt Cancer Center & ResearchInstitute, +1-813-745-1478, nancy.johnson@moffitt.org

Web site: http://www.moffitt.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb. 17, 2017   Risperdal lawsuits involving gynecomastia ... associated with use of the atypical antipsychotic medication continue ... Court of Common Pleas, where the state,s Risperdal ... According to a notice posted on the Court,s ... meeting on March 9, 2017 at 11:00 a.m. (In ...
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/16/2017)... -- Research and Markets has announced the addition ... report to their offering. ... Traditional medical devices include devices ... coated implantables, large endoscopes, needle based drug delivery, lab based ... two to three decades for the treatment and management of ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, a ... non-controlled substances plus the ability to manage orders on their desktop or mobile ... electronic prescriptions, according to the Office of the National Coordinator of Health IT, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of ... the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management ... recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national ... was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... made notable contributions to the staffing industry over the last twelve months. Industry ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... and financial planning assistance to families and business owners in the greater Fort ... 4 Families organization. , For more than 30 years, LifeNet 4 Families ...
(Date:2/16/2017)... Kisco, New York (PRWEB) , ... February 16, ... ... Hospital’s (NWH) nursing professionalism, teamwork and superiority in patient care, NWH has ... of the Commission on Magnet on Tuesday, January 31, 2017. The American Nurses ...
Breaking Medicine News(10 mins):